Genezen to Acquire Massachusetts Gene Therapy Manufacturing Operations from uniQure

Genezen, a gene therapy contract development and manufacturing organization (CDMO), and uniQure, a gene therapy company, announced on July 1, 2024 that they have entered into an agreement under which Genezen will acquire uniQure’s commercial gene therapy operations in Lexington, Mass., for a total consideration of $25 million. The transaction price consists of $12.5 million of newly issued Series C preferred stock and a convertible note valued at $12.5 million. Matt Kapusta, uniQure’s CEO, will join the board of Genezen at closing of transaction, which is expected early in the third quarter of 2024, according to an uniQure company press release.

Read More on Biopharm International